Improving global healthcare access thanks to a continuous and sustainable mRNA manufacturing solution.
Dillico was cofounded by senior industry experts for the purpose of developing and marketing a unique integrated and digitalized all-scale-range mRNA drug product manufacturing solution.
With its continuous and automated mRNA-LNP manufacturing system, Dillico is revolutionizing the landscape of the biopharma industry. Our proprietary flow technology and unique production process allow for the production of mRNA vaccines and therapies at any scale, from discovery to commercial manufacturing, using the same piece of equipment. This continuous all-scale solution significantly reduces the time and effort that goes into development, as well as offering unmatched flexibility in terms of production capacity.